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Inclusion criteria 
Studies:  
Randomized controlled trials. 
Participants: 
Adults, excluding pregnant women, with hypertension 
(high blood pressure) as defined by the study authors.   
Intervention: 
Beta-blockers either alone or as a first-line drug in a 
stepped care approach. 
Control: no treatment, placebo, or alternative 
antihypertensive drug.  
Outcomes: 
Primary: death. 
Secondary: coronary heart disease; stroke.  
Adverse events: any adverse events.  
Results 
• Thirteen trials including 91,561 participants met the 
inclusion criteria. Nine used adequate methods to 
conceal allocation. Atenolol was the beta-blocker 
used in 75% of the participants in this review. 
• Risk of death was no different for beta-blockers 
compared to no treatment or placebo (23,613 
participants, 4 trials), diuretics, or RAS inhibitors, 
but it was significantly higher compared to CCBs 
(relative risk 1.07, 95% confidence interval 1.00 to 
1.14; 44,825 participants, 4 trials). 
• The effect of beta-blockers on coronary heart 
disease was no different to placebo, diuretics, RAS 
inhibitors, or CCBs. 
• Participants treated with beta-blockers had a lower 
risk of developing stroke compared with placebo 
(RR 0.80, 95% CI 0.66 to 0.96; 23,613 participants, 
4 trials), but the risk was higher compared to CCBs 
(RR 1.24, 95% CI 1.11 to 1.40; 44,167 participants, 
3 trials) and RAS inhibitors (RR 1.30, 95% CI 1.11 
to 1.53; 9951 participants, 2 trials). 
• Participants on a beta-blockers were more likely to 
stop treatment due to adverse events than those on 
a diuretic (RR 1.86, 95% CI 1.39 to 2.50; 11,566 
participants, 3 trials) or a RAS inhibitor (RR 1.41, 
95% CI 1.29 to 1.54; 9951 participants, 2 trials), 
but there was no significant difference with CCBs. 
Do beta-blockers prevent heart disease and strokes 
in people with high blood pressure? 
In people with high blood pressure, there is no evidence that beta-blockers reduce the 
number of deaths. Beta-blockers reduce the risk of stroke but are less effective than 
calcium channel blockers (CCBs) or renin-angiotensin system (RAS) inhibitors.  
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Authors’ conclusions 
Implications for practice:  
The available evidence does not support the use of beta-blockers as first-line drugs for treating high blood 
pressure. 
Implications for research: 
More trials assessing the use of different subclasses of beta-blockers, compared with other antihypertensive 
drugs, are needed. The possible differential effects of beta-blockers on younger and older people should be 
assessed.  
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